Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
Eleni Andreopoulou(Cornell University), Franco M. Muggia(NYU Langone Health), E. Kim(Long Island Jewish Medical Center), John P. Curtin(Cork University Hospital), Allan J. Jacobs(Welsh Government), Darci Gaiotti(New York University), A. Hamilton(Royal Prince Alfred Hospital), Andrea Downey(University of New Mexico), D. Mirchandani
Cited by 83
Related Papers
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
|Annals of Oncology|2011|102
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
|Journal of Clinical Oncology|2005|100
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
|Journal of Clinical Oncology|1996|87
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
|JAMA|2024|75
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
|Journal of Clinical Oncology|2022|73